TY  - JOUR
AU  - Marcé, Sílvia
AU  - Xicoy, Blanca
AU  - García, Olga
AU  - Cabezón, Marta
AU  - Estrada, Natalia
AU  - Vélez, Patricia
AU  - Boqué, Concepción
AU  - Sagüés, Miguel
AU  - Angona, Anna
AU  - Teruel Montoya, Raúl
AU  - Ferrer Marín, Francisca
AU  - Amat, Paula
AU  - Hernández Boluda, Juan
AU  - Ibarra, Mariana
AU  - Anguita Mandly, Eduardo Luis
AU  - Cortés, Montserrat
AU  - Fernández Ruiz, Andrés
AU  - Fontanals, Sandra
AU  - Zamora, Lurdes
PY  - 2021
DO  - 10.3390/jcm10143146
SN  - 2077-0383
UR  - https://hdl.handle.net/20.500.14352/4786
T2  - Journal of Clinical Medicine
AB  - The most frequent BCR-ABL1-p210 transcripts in chronic myeloid leukemia (CML) are e14a2 and e13a2. Imatinib (IM) is the most common first-line tyrosine–kinase inhibitor (TKI) used to treat CML. Some studies suggest that BCR-ABL1 transcript types...
LA  - eng
M2  - 3146
PB  - MPDI
KW  - Chronic myeloid leukemia
KW  - BCR-ABL1 transcripts
KW  - Response to imatinib
KW  - Survival
KW  - Discontinuation
KW  - Relapse-free survival
TI  - Impact of BCR-ABL1 Transcript Type on Response, Treatment-Free Remission Rate and Survival in Chronic Myeloid Leukemia Patients Treated with Imatinib
TY  - journal article
VL  - 10
ER  -